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Abstract
Purpose—The prevalence of cancer survivorship and chronic health conditions is increasing. 
Limited information exists on the economic burden of chronic conditions among survivors of 
cancer. This study examines the prevalence and economic effect of chronic conditions among 
survivors of cancer.
Methods—Using the 2008 to 2013 Medical Expenditure Panel Survey, we present nationally 
representative estimates of the prevalence of chronic conditions (heart disease, high blood 
pressure, stroke, emphysema, high cholesterol, diabetes, arthritis, and asthma) and multiple 
chronic conditions (MCCs) and the incremental annual health care use, medical expenditures, and 
lost productivity for survivors of cancer attributed to individual chronic conditions and MCCs. 
Incremental use, expenditures, and lost productivity were evaluated with multivariable regression.
Results—Survivors of cancer were more likely to have chronic conditions and MCCs compared 
with adults without a history of cancer. The presence of chronic conditions among survivors of 
cancer was associated with substantially higher annual medical expenditures, especially for heart 
disease ($4,595; 95% CI, $3,262 to $5,927) and stroke ($3,843; 95% CI, $1,983 to $5,704). The 
presence of four or more chronic conditions was associated with increased annual expenditures of 
$10,280 (95% CI, $7,435 to $13,125) per survivor of cancer. Annual lost productivity was higher 
among survivors of cancer with other chronic conditions, especially stroke ($4,325; 95% CI, 
$2,687 to $5,964), and arthritis ($3,534; 95% CI, $2,475 to $4,593). Having four or more chronic 
conditions was associated with increased annual lost productivity of $9,099 (95% CI, $7,224 to 
$10,973) per survivor of cancer. The economic impact of chronic conditions was similar among 
survivors of cancer and individuals without a history of cancer.
Conclusion—These results highlight the importance of ensuring access to lifelong personalized 
screening, surveillance, and chronic disease management to help manage chronic conditions, 
reduce disruptions in employment, and reduce medical expenditures among survivors of cancer.
INTRODUCTION
The prevalence of chronic conditions is increasing in the United States.1 More than one 
quarter of all adults (26%) and nearly two thirds of adults age ≥ 65 years (61%) have 
multiple (two or more) chronic conditions (MCCs).1 Chronic conditions are particularly 
common among the estimated 14.5 million people who have received a cancer diagnosis 
(survivors of cancer), nearly three quarters of whom (72%) are age ≥ 60 years.2 MCCs in 
this population have wide-ranging implications for treatment decision making, health care 
use, disease management, and quality of life.3
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Survivors of cancer also face economic hardship as a result of limitations in employment, 
reduced income, and increased out-of-pocket health care costs.4–9 Among survivors of 
cancer, 32% reported limitations in daily activities, 25% reported that cancer interfered with 
their ability to perform required tasks, and 42% of employed survivors reported changing 
their work schedule because of cancer.10 People with other chronic conditions report similar 
health and functional impairments that negatively affect their ability to work and increase 
their health care expenses. However, limited information is available on the economic 
burden of MCCs,11–13 particularly among survivors of cancer.
Understanding the prevalence and burden of chronic conditions is an important 
consideration for national efforts, such as those by the US Department of Health and Human 
Services (HHS) to optimize health and quality of life among the growing population of 
people with MCCs.14–16 This information can help improve patient care and care delivery 
and minimize the social and economic burden of lost productivity and health care costs.
The objectives of this study were to examine the prevalence of chronic conditions among 
adult survivors of cancer and people without a history of cancer and to estimate the effect of 
chronic conditions on health care use, medical care costs, and productivity loss among 
survivors of cancer in the United States.
METHODS
Data
The data source for these analyses was the 2008 to 2013 Medical Expenditure Panel Survey 
(MEPS) Household Component. MEPS representatives contacted a nationally representative 
sample of the US civilian noninstitutionalized population to collect detailed information on 
demographic characteristics, health status, health insurance, health care use and 
expenditures, and employment. In-person interviews were conducted with one person who 
responded for all members of the household. During the study years included in our 
analysis, the annual response rate ranged from 52.8% to 59.3%. Information from the 
Medical Provider Component was used to supplement, verify, or replace information 
provided by household respondents on the health services received and the cost of these 
services.17 A detailed description of MEPS is available elsewhere.18,19
Analytic Sample
A survivor of cancer was defined as any person who has ever been diagnosed with cancer. 
We identified 10,293 survivors of cancer based on the question, “Has a doctor or other 
health provider ever told you that you have a cancer or malignancy of any kind?” The 
comparison group consisted of the remaining 135,151 adults who did not report a history of 
cancer. Similar to previous studies, people diagnosed solely with nonmelanoma skin cancer 
were not classified as survivors of cancer and were put in the comparison group.8,20
Descriptive statistics were calculated for survivors of cancer and people without a history of 
cancer and compared using χ2 statistics. Sociodemographic characteristics of survivors of 
cancer at the time of the survey included time since diagnosis, cancer site, age, sex, race/
ethnicity, educational attainment, marital status, health status, health insurance status, family 
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income, and the presence of chronic conditions. Chronic conditions included all those 
specified as priority conditions by MEPS and were identified through a series of questions 
about whether a physician or other health care professional ever told the person that he or 
she had any of the following: arthritis, asthma, diabetes, emphysema, heart disease 
(including coronary heart disease, angina, myocardial infarction, and other unspecified heart 
disease), high blood pressure, stroke, or high cholesterol. The prevalence of each condition 
was estimated among survivors of cancer and people without a history of cancer. The 
prevalence of MCCs was examined by summing the number of chronic conditions reported 
by each person (zero, one, two, three, or four or more conditions). All adjusted analyses 
controlled for survey year, age, sex, race/ethnicity, marital status, and education. Analyses 
were conducted using Stata, version 14.0 (StataCorp, College Station, TX).
Health Care Use and Medical Expenditures
Several measures of health care use were examined among survivors of cancer based on the 
reported use of health care services in the past year. These measures were the number of 
ambulatory visits, including office-based provider and outpatient visits; number of 
emergency room visits; number of inpatient hospital nights; and number of prescription 
medications. Generalized linear models with a negative binomial distribution and a log link 
were used to estimate the number of ambulatory visits and prescription medications. Two-
part models were used to estimate emergency room visits and inpatient hospital stays, given 
the large number of observations without any use of these services. The first part of the 
model used logistic regression to predict the probability of any use, and the second part 
estimated use with a generalized linear model with a negative binomial distribution and a log 
link among those with use. Total annual medical expenditures for all health care services 
were estimated using generalized linear models with a gamma distribution and a log link. 
Separate models were used to evaluate incremental health care use and medical care 
expenditures for each of the chronic conditions plus the incremental effect of MCCs. All 
medical expenditures were adjusted to 2013 US dollars using the Personal Health Care 
Expenditure Price Index.21
Productivity Loss
Productivity loss was examined by assessing employment disability, missed work days, and 
additional days spent in bed among survivors of cancer. Employment disability was defined 
as being unable to work because of illness or injury. Lost productivity from employment 
disability was transformed to days by multiplying the adjusted percentage of people who 
reported employment disability by 260, the number of work days per year. Missed work 
days were defined as the number of days (half-day or more) of work that people who were 
employed missed because of illness, injury, or mental or emotional problems. Lost 
household productivity was assessed by determining the number of additional missed days, 
other than work or school, in which at least a half-day was spent in bed because of illness or 
injury. Multivariable logistic regression modeling was used to estimate employment 
disability, whereas generalized linear models with a negative binomial distribution and a log 
link were used to estimate missed work days and additional days spent in bed. Separate 
models were used to evaluate lost productivity for each of the chronic conditions and for the 
incremental effect of MCCs.
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Total costs from productivity loss were calculated as the sum of productivity loss from 
employment disability, missed work days, and additional days spent in bed. Productivity loss 
from employment disability was estimated by multiplying the adjusted percentage of people 
who reported employment disability by the median annual wage in 2013 ($35,080) from the 
Bureau of Labor Statistics.22 Lost productivity from missed work days was estimated by 
multiplying the adjusted mean number of missed days by the cost per day using the median 
hourly wage ($16.87) from the US Bureau of Labor Statistics.22 Because MEPS does not 
differentiate between missed full and partial days, we assumed each missed work day to be 6 
hours. Lost household productivity was calculated by multiplying the mean number of 
additional days spent in bed by the value of daily household productivity ($43.37 per day)23 
adjusted to 2013 US dollars using the Consumer Price Index.24
Multivariable Analyses
Analyses examining the effect of chronic conditions on health care use, medical 
expenditures, and lost productivity among survivors of cancer were restricted to survivors of 
cancer. Additional analyses were performed to examine whether the economic burden of 
chronic conditions differed among survivors of cancer and individuals without a history of 
cancer. In these models, an additional dichotomous variable was included to identify 
survivors of cancer, and an interaction term between the dichotomous variable and chronic 
conditions variables that provides the incremental impact of chronic conditions related to 
cancer survivorship. Similar to previous studies,25 these models were estimated using linear 
regression to aid in interpretation.
All adjusted estimates are presented as predictive margins, which standardizes these 
estimates to the covariate distribution of the overall population.26 Statistical significance was 
set at P ≤ .05, using two-tailed tests. Model goodness of fit was assessed with the Hosmer-
Lemeshow test. All analyses used MEPS person-level weights to account for the complex 
study design and to reflect the probability of selection and adjustments for nonresponse and 
poststratification to provide nationally representative estimates.
RESULTS
Characteristics of Survivors of Cancer and People Without a History of Cancer
Compared with people without a history of cancer, survivors of cancer were more likely to 
be older, female, non-Hispanic white, married, and in poorer health (Table 1). Among adult 
survivors of cancer younger than age 65 years, the presence of four or more chronic 
conditions was most common among those with Medicaid (17.1%), followed by the 
uninsured (14.7%) and those with private insurance (11.0%; data not shown). Among 
survivors of cancer age ≥ 65 years, having four or more chronic conditions was more 
common among people with Medicare and public insurance (31.5%) than among those with 
Medicare and private insurance (28.6%) or Medicare only (26.5%). Among survivors of 
cancer, the most common cancer sites were the breast (18.3%) and prostate (13.9%). Nearly 
one third of survivors of cancer (30.1%) were diagnosed within the past 4 years, whereas 
39.2% were diagnosed ≥ 10 years before the survey (Table 2).
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Prevalence of Chronic Conditions
Table 3 lists the unadjusted and adjusted prevalence of chronic conditions among survivors 
of cancer and people without a history of cancer. The unadjusted and adjusted prevalence 
estimates highlight the importance of controlling for differences (eg, age) between the two 
populations. Survivors of cancer were more likely than people without a history of cancer to 
have each chronic condition; after adjustment, the most common conditions for both groups 
were high blood pressure (35.7% v 32.7%, respectively), high cholesterol (35.0% v 30.5%, 
respectively), and arthritis (29.4% v 24.9%, respectively). Survivors of cancer were more 
likely to have MCCs, with 12.7% reporting four or more conditions compared with 9.5% of 
people without a history of cancer.
Health Care Use and Medical Care Costs
Among survivors of cancer, having a chronic condition, particularly MCCs, was associated 
with increased health care use (Table 4). Survivors of cancer with four or more chronic 
conditions had 10.5 additional ambulatory visits (95% CI, 8.7 to 12.3 visits; P < .001), 0.1 
additional emergency room visits (95% CI, 0.03 to 0.1 visits; P = .002), and 50.1 additional 
prescription medications (including refills) (95% CI, 45.3 to 54.9 medications; P < .001) per 
year compared with survivors of cancer without chronic conditions.
Among survivors of cancer, several chronic conditions were associated with higher medical 
expenditures. Heart disease ($4,595; 95% CI, $3,262 to $5,927) and stroke ($3,843; 95% CI, 
$1,983 to $5,704) were associated with the largest annual expenditures (P < .001 for both). 
Annual medical care costs were $10,280 (95% CI, $7,435 to $13,125) higher among 
survivors of cancer with four or more chronic conditions than among survivors with no 
chronic conditions (P < .001). The incremental effect of chronic conditions on health care 
use and expenditures was similar among survivors of cancer and individuals without a 
history of cancer (Appendix Table A1, online only).
Productivity Loss
The presence of chronic conditions was associated with higher productivity loss in survivors 
of cancer, particularly those with MCCs (Table 5). Compared with survivors of cancer 
without chronic conditions, survivors of cancer with four or more chronic conditions 
reported an additional 56.1 days (95% CI, 45.7 to days) of productivity loss because of 
employment disability, 7.4 additional missed work days (95% CI, 4.5 to 10.3 days), and 18.0 
additional lost household productivity days (95% CI, 13.6 to 22.4 days) each year (P < .001 
for all). Annual lost productivity costs among survivors of cancer with four or more chronic 
conditions were $9,099 (95% CI, $7,224 to $10,973) higher than survivors with no chronic 
conditions (P < .001).
The majority of chronic conditions were associated with more days lost because of 
employment disability and lost household productivity. Stroke ($4,325; 95% CI, $2,687 to 
$5,964) and arthritis ($3,534; 95% CI, $2,475 to $4,593) were associated with the highest 
annual costs (P < .001 for both). The incremental effect of chronic conditions on lost 
productivity was largely the same among survivors of cancer and individuals without a 
history of cancer (Appendix Table A2).
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DISCUSSION
This study demonstrates that survivors of cancer are more likely than individuals without a 
history of cancer to have other chronic conditions, with 12.7% reporting four or more 
chronic conditions in addition to cancer. Among survivors of cancer, chronic conditions, 
particularly MCCs, were associated with increased health care use, medical expenditures, 
and lost productivity. Having four or more chronic conditions was associated with $10,280 
in annual excess medical expenditures and $9,099 in excess lost productivity costs. The 
incremental economic burden of chronic conditions was similar among survivors of cancer 
and individuals without a history of cancer. However, the increased prevalence of chronic 
conditions among survivors of cancer and their affect underscore the importance of ongoing 
efforts to improve survivorship care planning and employer wellness programs to minimize 
the negative effects of MCCs.
Although previous studies have found that chronic conditions are associated with higher 
medical expenditures, more employment limitations, and lost productivity among survivors 
of cancer,25,27 our study is the first, to our knowledge, to estimate the resulting lost 
productivity costs. We found that chronic conditions among survivors of cancer were 
associated with substantial lost productivity costs from employment disability, missed work 
days, and days spent in bed because of poor health. Our estimates of annual lost productivity 
costs associated with MCCs are of similar magnitude to those for excess medical 
expenditures, suggesting that future evaluations of interventions to manage chronic 
conditions include measures of productivity as outcomes.
Given the medical care needs of survivors of cancer, particularly those with chronic 
conditions, access to lifelong personalized screening and surveillance is needed. A higher 
prevalence of MCCs among survivors of cancer with Medicaid likely reflects eligibility rules 
that expand coverage to individuals in poor health, such as the medically needy and 
disabled. In addition, the higher rate of chronic conditions among survivors of cancer 
without health insurance underscores the importance of insurance in ensuring access to 
appropriate health care among this population. The Affordable Care Act (ACA) has made 
insurance available to more people by setting up a Health Insurance Marketplace and by 
providing states the opportunity to expand Medicaid. Additional components of the ACA, 
such as preventing insurance companies from denying coverage or charging more for pre-
existing conditions, have also helped ensure access to health insurance among survivors of 
cancer with chronic conditions. In addition, cancer survivors with Medicare benefit from the 
elimination of the coverage gap in Medicare Part D to help make their prescription drugs 
more affordable.
The increased prevalence and burden of chronic conditions among survivors of cancer 
highlight the importance of chronic disease management in improving quality of life and 
reducing the need for care.28 Community-based chronic disease self-management programs 
linked to clinical services can give survivors of cancer with chronic conditions the 
knowledge and skills to manage their conditions.28 Effective self-management programs can 
improve quality of life and health status, while reducing health care use and improving 
productivity.29–31 Our study found that the presence of MCCs among survivors of cancer is 
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associated with increases in the number of prescribed medications. To improve adherence 
and knowledgeable use of medication, reminders and patient education can be used to 
reduce adverse drug effects, medication errors, and chronic disease progression.15
The National Academy of Medicine (formally known as the Institute of Medicine) has 
highlighted the complexities and need for care coordination for people with MCCs, given 
evidence that patients who receive care for a single chronic condition may not receive care 
for other, unrelated conditons.31 As part of its national initiative on MCCs, HHS released a 
strategic framework for maximizing care coordination and improving the health and quality 
of life of people with MCCs.15 HHS also partnered with the National Academy of Medicine 
to identify principles and action steps to improve clinical practice guidelines for patients 
with MCCs and to increase the focus on patient-centered care.14
The ACA has accelerated efforts to coordinate and manage care for people with MCCs 
through models such as accountable care organizations and patient-centered medical homes.
16
 Several models are being examined, such as the COME HOME program, which uses a 
community oncology medical home model to actively integrate changes in infrastructure, 
clinical, and payment systems to deliver better patient-centered, coordinated, and 
comprehensive care.16,32 In addition, the ACA established a Medicaid Health Home plan 
that states can use to establish health homes for people with MCCs, with the goal of 
improving care coordination and reducing costs among populations most in need.16,33
Our study found that the presence of chronic conditions among survivors of cancer is 
associated with lower worker productivity. To help curb increasing health care costs and 
increase worker productivity, many businesses offer workplace wellness programs. These 
programs are designed to support healthy behaviors and improve health outcomes among 
employees and have been shown to be cost beneficial, with a positive return on investment.34 
Workplace health promotion efforts among survivors of cancer could focus on encouraging 
screening for secondary cancers and reducing chronic disease risk factors, such as tobacco 
use, physical inactivity, and poor nutrition. Despite their potential health benefits and cost 
savings, such programs are underused.34 Increased efforts in this area are needed for 
survivors of cancer, given their increased risk of developing other chronic conditions and 
secondary cancers.35–37
Our study has limitations. First, the reliance on household-reported data introduces potential 
reporting biases and may reduce the reliability of some measures. However, studies have 
shown agreement between household reports and medical records,38,39 including 
prescription drug use.40,41 Second, our results only apply to the noninstitutionalized civilian 
adult population. Third, population-based household surveys generally underestimate rare 
and short-survival, high-cost cancers; they mainly consist of data from long-term survivors 
of common adult cancers many years after diagnosis.42,43 Fourth, the MEPS does not have 
information on stage of cancer diagnosis or the full cancer treatment history, which may be 
associated with developing other chronic conditions. Fifth, our measures of lost productivity 
are limited and not condition specific. However, we measured lost productivity the same way 
for survivors of cancer and individuals without a history of cancer and examined each 
measure separately. Improving longitudinal measures of lost productivity is an important 
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area for future research. Sixth, the cross-sectional design of the study limits causal analysis. 
Seventh, although we control for several sociodemographic differences between survivors of 
cancer and individuals without a history of cancer, there may be unmeasured factors that we 
are unable to account for. Finally, we likely underestimated the burden of chronic conditions 
among survivors of cancer because we did not include patient and caregiver time and 
transportation costs for medical appointments and additional aspects of productivity loss.44
Chronic conditions are more common among survivors of cancer and are associated with 
increased medical expenditures and lost productivity. Access to lifelong personalized 
screening, surveillance, and chronic disease self-management may be effective in managing 
chronic conditions, reducing medical expenditures, and minimizing disruptions in 
employment among survivors of cancer.
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Table 1.
Demographic Characteristics of Survivors of Cancer and People Without a History of Cancer: Medical 
Expenditure Panel Survey, 2008 to 2013
Survivors of Cancer (n = 10,293) People Without a History ofCancer (n = 135,151)
Characteristic % 95% CI % 95% CI P
Age, years < .001
 18-39 7.2 6.4 to 8.0 41.7 40.8 to 42.5
 40-44 3.9 3.4 to 4.6 9.1 8.8 to 9.3
 45-49 5.4 4.8 to 6.1 9.2 8.9 to 9.5
 50-54 7.9 7.0 to 8.9 9.9 9.5 to 10.2
 55-59 10.2 9.3 to 11.1 8.4 8.2 to 8.7
 60-64 12.7 11.6 to 13.8 6.9 6.6 to 7.3
 65-69 12.5 11.4 to 13.6 5.0 4.8 to 5.3
 70-74 11.9 11.0 to 12.9 3.4 3.3 to 3.6
 75-79 10.2 9.2 to 11.2 2.6 2.4 to 2.8
 ≥ 80 18.2 16.3 to 20.3 3.7 3.4 to 4.0
Sex < .001
 Male 42.1 40.5 to 43.7 48.9 48.5 to 49.2
 Female 57.9 56.3 to 59.5 51.1 50.8 to 51.5
Race/ethnicity < .001
 Non-Hispanic white 84.5 83.1 to 85.8 65.4 63.5 to 67.2
 Non-Hispanic black 7.1 6.3 to 7.9 11.9 10.7 to 13.2
 Hispanic 5.5 4.8 to 6.3 15.3 13.7 to 16.9
 Non-Hispanic other 3.0 2.3 to 3.9 7.5 6.5 to 8.5
Education .002
 Less than high school graduate 14.5 13.4 to 15.7 16.2 15.6 to 16.9
 High school graduate 30.7 29.1 to 32.3 28.6 27.9 to 29.4
 Some college or more 54.5 52.6 to 56.4 54.7 53.6 to 55.7
Marital status < .001
 Married 57.5 55.1 to 59.8 52.4 51.5 to 53.3
 Not married 42.5 40.2 to 44.9 47.6 46.7 to 48.5
Health status < .001
 Excellent/very good 40.2 38.6 to 41.7 60.0 59.2 to 60.8
 Good 32.0 30.7 to 33.3 27.7 27.1 to 28.3
 Fair/poor 27.6 26.3 to 29.0 12.2 11.9 to 12.6
Health insurance
 Age < 65 years < .001
  Any private 73.6 71.5 to 75.6 70.3 69.0 to 71.4
  Public only 15.6 14.0 to 17.3 10.8 10.2 to 11.5
  Uninsured 10.8 9.5 to 12.3 18.9 18.0 to 19.9
 Age ≥ 65 years < .001
  Medicare and private 55.3 52.5 to 58.1 50.1 48.4 to 51.8
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Survivors of Cancer (n = 10,293) People Without a History ofCancer (n = 135,151)
Characteristic % 95% CI % 95% CI P
  Medicare and public 8.5 7.4 to 9.8 11.0 10.0 to 12.1
  Medicare only 35.4 32.8 to 38.0 37.3 35.9 to 38.8
Family income < .001
 Poor (< 100% FPL) 10.9 10.1 to 11.8 12.6 12.0 to 13.3
 Near poor (100% to 200% FPL) 20.0 18.8 to 21.3 17.9 17.4 to 18.5
 Not poor (> 200% FPL) 69.1 67.4 to 70.7 69.5 68.5 to 70.4
Abbreviation: FPL, federal poverty level.
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Table 2.
Characteristics of Survivors of Cancer: Medical Expenditure Panel Survey, 2008 to 2013
Survivors of Cancer
(N = 10,293)
Characteristic % 95% CI
Cancer site*
 Bladder 2.1 2.2 to 3.1
 Blood/leukemia/lymphoma 4.5 3.9 to 5.2
 Breast 18.3 17.1 to 19.7
 Cervix 7.2 6.5 to 8.1
 Colorectal 6.3 5.6 to 7.1
 Kidney 1.5 1.2 to 1.9
 Lung 2.9 2.5 to 3.4
 Melanoma 9.0 8.1 to 10.0
 Ovary 1.6 1.3 to 2.0
 Prostate 13.9 12.8 to 15.1
 Thyroid 2.3 1.9 to 2.9
 Uterus 4.2 3.7 to 4.8
 Other 32.1 30.6 to 33.6
Time since cancer diagnosis, years†
 0-4 30.1 28.5 to 31.7
 5-9 21.6 20.4 to 22.8
 10-19 22.0 20.6 to 23.4
 ≥ 20 17.2 16.0 to 18.5
 Missing 9.1 7.8 to 10.5
 Mean, years 10.8 10.5 to 11.2
*
Percentages sum to greater than 100% as a result of some individuals reporting more than one cancer diagnosis.
†
Time since diagnosis was not available in the 2013 Medical Expenditure Panel Survey public use file. The results for time since diagnosis reflect 
2008 to 2012 data (n = 8,617).
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m
 o
f l
os
t p
ro
du
ct
iv
ity
 fr
om
 e
m
pl
oy
m
en
t d
isa
bi
lit
y, 
m
iss
ed
 w
o
rk
 d
ay
s, 
an
d 
lo
st 
ho
us
eh
ol
d 
pr
od
uc
tiv
ity
.
 
Lo
st
 p
ro
du
ct
iv
ity
 
fro
m
 e
m
pl
oy
m
en
t d
isa
bi
lit
y 
is 
th
e 
ad
jus
ted
 pe
rce
nta
ge
 of
 pe
op
le 
un
ab
le 
to 
wo
rk
 b
ec
au
se
 o
f i
lln
es
s o
r i
nju
ry 
mu
ltip
lie
d b
y 2
60
 (n
um
be
r o
f w
o
rk
 d
ay
s i
n 
th
e 
ye
ar
); 
co
st 
is 
the
 m
ed
ian
 an
nu
al 
wa
ge
 ($
35
,08
0) 
m
u
lti
pl
ie
d 
by
 th
e 
ad
jus
ted
 pe
rce
nta
ge
 of
 pe
op
le 
un
ab
le 
to 
wo
rk
 b
ec
au
se
 o
f i
lln
es
s o
r i
nju
ry.
 
Lo
st
 p
ro
du
ct
iv
ity
 fr
om
 lo
st 
w
o
rk
da
ys
 is
 th
e 
m
ed
ia
n 
na
tio
na
l d
ai
ly
 w
ag
e 
($1
6.8
7 p
er 
ho
ur 
× 6
 ho
urs
 = 
$1
01
.22
 pe
r 
da
y) 
mu
ltip
lie
d b
y t
he
 ad
jus
ted
 nu
mb
er 
of 
da
ys 
los
t fr
om
 w
o
rk
. L
os
t h
ou
se
ho
ld
 p
ro
du
ct
iv
ity
 is
 th
e 
va
lu
e 
of
 d
ai
ly
 h
om
e 
pr
od
uc
tiv
ity
 ($
43
.37
) m
ult
ipl
ied
 by
 th
e a
dju
ste
d n
um
be
r o
f a
dd
itio
na
l d
ay
s s
pe
nt 
in 
be
d.
 R
eg
re
ss
io
n 
an
al
ys
es
 c
on
tro
lle
d 
fo
r s
ur
ve
y 
ye
ar
,
 
ag
e,
 se
x
, 
ra
ce
/e
th
ni
ci
ty
,
 
m
ar
ita
l s
ta
tu
s, 
ed
uc
at
io
n,
 a
nd
 o
th
er
 c
om
or
bi
d 
co
nd
iti
on
s.
*
Lo
st
 h
ou
se
ho
ld
 p
ro
du
ct
iv
ity
 w
as
 n
o
t i
nc
lu
de
d 
in
 th
e 
20
13
 M
ed
ic
al
 E
xp
en
di
tu
re
 P
an
el
 S
ur
ve
y.
 
R
es
ul
ts 
fo
r t
hi
s v
ar
ia
bl
e 
ar
e 
fo
r 2
00
8 
to
 2
01
2.
† H
ea
rt 
di
se
as
e 
in
cl
ud
es
 c
or
on
ar
y 
he
ar
t d
ise
as
e,
 a
ng
in
a,
 m
yo
ca
rd
ia
l i
nf
ar
ct
io
n,
 a
nd
 o
th
er
 u
ns
pe
ci
fie
d 
he
ar
t d
ise
as
e.
J Clin Oncol. Author manuscript; available in PMC 2018 July 25.
